HTLV-1 gene expression in adult T-cell leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice.

PubWeight™: 0.89‹?›

🔗 View Article (PMID 8955035)

Published in Virology on December 15, 1996

Authors

S A Stewart1, G Feuer, A Jewett, F V Lee, B Bonavida, I S Chen

Author Affiliations

1: Department of Microbiology & Immunology, University of California at Los Angeles School of Medicine 90095-1747, USA.

Articles citing this

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood (2007) 1.54

Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene (2005) 1.15

Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. J Virol (2007) 1.08

Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model. Blood (2009) 0.95

Mouse model for the equilibration interaction between the host immune system and human T-cell leukemia virus type 1 gene expression. J Virol (2002) 0.92

Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis. Front Microbiol (2012) 0.88

Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma. Vet Pathol (2010) 0.88

Animal models on HTLV-1 and related viruses: what did we learn? Front Microbiol (2012) 0.88

HTLV-1 and innate immunity. Viruses (2011) 0.85

Studies of retroviral infection in humanized mice. Virology (2015) 0.83

HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status. Front Microbiol (2013) 0.82

Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia (2007) 0.81

What we are learning on HTLV-1 pathogenesis from animal models. Front Microbiol (2012) 0.81

Animal Models Utilized in HTLV-1 Research. Virology (Auckl) (2013) 0.77

Articles by these authors

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60

Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77

HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72

Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78

The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42

Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci U S A (1985) 4.28

Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene (2006) 4.06

Clearance of HIV infection in a perinatally infected infant. N Engl J Med (1995) 3.76

The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43

Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science (1984) 3.39

High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature (1990) 3.28

Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28

Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science (1988) 3.22

Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev (1991) 3.06

High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science (1989) 3.00

Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82

Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol (1989) 2.67

Nucleotide sequence analysis of the long terminal repeat of human T-cell leukemia virus type II. Proc Natl Acad Sci U S A (1984) 2.67

High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol (1996) 2.57

Characterization of reticuloendotheliosis virus strain T DNA and isolation of a novel variant of reticuloendotheliosis virus strain T by molecular cloning. J Virol (1981) 2.49

Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature (1986) 2.49

The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol (1992) 2.49

Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45

The x gene is essential for HTLV replication. Science (1985) 2.44

Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol (1989) 2.42

Human T-cell leukemia virus type II transforms normal human lymphocytes. Proc Natl Acad Sci U S A (1983) 2.41

Long terminal repeats of human T-cell leukaemia virus II genome determine target cell specificity. Nature (1984) 2.39

HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation. Science (1988) 2.37

Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature (1983) 2.36

Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol (1994) 2.36

Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol (1996) 2.33

Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest (1992) 2.28

Establishment of infection by spleen necrosis virus: inhibition in stationary cells and the role of secondary infection. J Virol (1982) 2.26

Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1993) 2.15

Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem (1976) 2.14

Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod (1994) 2.12

Binding of host-cell factors to DNA sequences in the long terminal repeat of human T-cell leukemia virus type I: implications for viral gene expression. Proc Natl Acad Sci U S A (1988) 2.12

Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11

A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol (2001) 2.11

Nucleotide sequence of the 3' region of an infectious human T-cell leukemia virus type II genome. Proc Natl Acad Sci U S A (1984) 2.10

Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med (2000) 2.10

Rapid generation of sequence variation during primary HIV-1 infection. AIDS (1992) 2.08

Functional relation between HTLV-II x and adenovirus E1A proteins in transcriptional activation. Science (1985) 1.87

Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science (1998) 1.83

Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol (1979) 1.80

Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy (2011) 1.73

HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease. J Acquir Immune Defic Syndr (1991) 1.72

Structure of a human DNA repair protein UBA domain that interacts with HIV-1 Vpr. Nat Struct Biol (1998) 1.69

Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69

Substitution of 5' helper virus sequences into non-rel portion of reticuloendotheliosis virus strain T suppresses transformation of chicken spleen cells. Cell (1982) 1.69

Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol (1992) 1.66

HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J (1991) 1.66

Studies of the putative transforming protein of the type I human T-cell leukemia virus. Science (1985) 1.65

Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci U S A (1991) 1.62

An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol (1999) 1.61

Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol (2000) 1.61

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res (2001) 1.59

Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res (2001) 1.59

Regulation of AIDS virus expression. Cell (1986) 1.57

Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. J Virol (2000) 1.55

Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol (1988) 1.54

Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.53

Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci U S A (1999) 1.52

Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. J Virol (1997) 1.52

Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol (1992) 1.52

Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol (2001) 1.50

Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J Virol (1990) 1.48

Human tear lysozyme. II. Quantitative determination with standard Schirmer strips. Am J Ophthalmol (1968) 1.46

HTLV x-gene product: requirement for the env methionine initiation codon. Science (1985) 1.45

Expression of the 3' terminal region of human T-cell leukemia viruses. Science (1984) 1.44

Evidence for several cell populations active in antibody dependent cellular cytotoxicity. J Immunol (1973) 1.44

A second isolate of HTLV-II associated with atypical hairy-cell leukemia. N Engl J Med (1986) 1.44

Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells. J Immunol (1982) 1.42

HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes. Science (1988) 1.41

Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med (1997) 1.41

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm (1997) 1.40

Structure and expression of c-rel, the cellular homolog to the oncogene of reticuloendotheliosis virus strain T. J Virol (1983) 1.40

Characterization of a novel HTLV-infected cell line. Blood (1984) 1.40

Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol (1992) 1.39

Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J Virol (1997) 1.37

Regulation of human T cell leukemia virus expression. FASEB J (1990) 1.36

Detection and cloning of new HTLV-related endogenous sequences in man. Nucleic Acids Res (1989) 1.36

Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol (1990) 1.35

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. J Immunol (1986) 1.34

Cellular immunoadsorbents: a simplified technique for separation of lymphoid cell populations. J Immunol (1974) 1.34

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene (2009) 1.34

Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood (1994) 1.33

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33

Human T-cell leukemia virus type II nucleotide sequences between env and the last exon of tax/rex are not required for viral replication or cellular transformation. J Virol (1995) 1.32

Effects of confinement in chaperonin assisted protein folding: rate enhancement by decreasing the roughness of the folding energy landscape. J Mol Biol (2003) 1.32

A new reporter system for detection of retroviral infection. Gene Ther (1995) 1.32

Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol (1992) 1.32

Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol (2001) 1.30

The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype. J Exp Med (1988) 1.30

Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol (1996) 1.30

Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. J Immunol (1979) 1.29